Literature DB >> 12535748

Aldosterone induces contraction of the resistance arteries in man.

Paola Romagni1, Fabio Rossi, Lara Guerrini, Chiara Quirini, Vittorio Santiemma.   

Abstract

Very rapid nongenomic effects of aldosterone in vitro have been described in recent years and in vivo evidence has been reported as well. In the present study, we investigated the rapid effect of aldosterone on resistance arteries in vivo in man. We performed a randomized, placebo-controlled, double-blind crossover study on ten healthy male volunteers. Forearm blood flow (FBF) was measured using venous occlusion plethysmography in both forearms. FBF was reduced by administration of aldosterone 2.5 pmol/min at min 4 (from 4.45+/-0.03 to 3.3+/-0.25 ml/100 ml tissue) and reached its nadir at min 12 (from 4.45+/-0.03 to 1.6+/-0.08 ml/100 ml tissue, P<0.001). Our study documents a direct nongenomic effect of aldosterone on the resistance arteries in vivo in man. The rapid vasoconstrictive effect of aldosterone at physiological concentrations opens the way to investigations on the vascular role of this steroid in several disorders, such as hypertension, characterized by elevated peripheral vascular resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12535748     DOI: 10.1016/s0021-9150(02)00363-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  24 in total

1.  Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers.

Authors:  Bruno Laviolle; Erwan Donal; Pascale Le Maguet; Fabrice Lainé; Eric Bellissant
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  The role of aldosterone antagonists in the management of resistant hypertension.

Authors:  Mari K Nishizaka; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 3.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

Review 4.  Mineralocorticoid Antagonism and Diabetic Kidney Disease.

Authors:  Yuliya Lytvyn; Lucas C Godoy; Rosalie A Scholtes; Daniël H van Raalte; David Z Cherney
Journal:  Curr Diab Rep       Date:  2019-01-23       Impact factor: 4.810

Review 5.  Hypertension and the expanding role of aldosterone.

Authors:  Scott M Mackenzie; John Connell
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 6.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

7.  Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone.

Authors:  Erwan Heylen; An Huang; Dong Sun; Gabor Kaley
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

Review 8.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 9.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

Review 10.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.